NCT06072781 2026-04-02
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
Clinical Trials
10 trialsNCT05768139 2026-03-02
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT03624244 2026-02-17
BFR-ESS
Centre Leon Berard
Phase 2 Recruiting
NCT04469764 2025-07-29
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT03909152 2025-07-28
A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04719273 2025-01-08
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Thomas Jefferson University
Phase 2 Active not recruiting
NCT02730923 2024-02-13
VICTORIA
Centre Leon Berard
Phase 1/2 Unknown
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT02476955 2020-09-30
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT00181688 2012-12-05
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer
Massachusetts General Hospital
Phase 2 Completed